These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15753399)

  • 1. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.
    Pohl G; Ho CL; Kurman RJ; Bristow R; Wang TL; Shih IeM
    Cancer Res; 2005 Mar; 65(5):1994-2000. PubMed ID: 15753399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
    Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
    Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
    Liu D; Liu Z; Jiang D; Dackiw AP; Xing M
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4686-95. PubMed ID: 17911174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
    Anglesio MS; Arnold JM; George J; Tinker AV; Tothill R; Waddell N; Simms L; Locandro B; Fereday S; Traficante N; Russell P; Sharma R; Birrer MJ; ; deFazio A; Chenevix-Trench G; Bowtell DD
    Mol Cancer Res; 2008 Nov; 6(11):1678-90. PubMed ID: 19010816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The molecular pathology of ovarian serous borderline tumors.
    Malpica A; Wong KK
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
    Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
    Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Jamieson S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
    Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
    J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular diagnosis in type I epithelial ovarian cancer.
    Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
    Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.